If I'd taken this advice, I wouldn't be ~60% up on #BIDS in <3 months.
I personally think micro-cap investors should always be considering i) market sentiment; ii) TAM and potential earnings; and iii) existing fundamentals - EQUALLY. 1/5
I would suggest that a fund manager as highly rated as Katie Potts at Herald understood and considered each of the above, when she invested £1m of client money in #BIDS at 4p recently. I imagine that investors with Herald are very happy that she made the decision to do so. 2/5
Next: a great many of the Cos listed on AIM primarily have their listing to tap investors for growth capital. This should always be a consideration for micro-cap investors. To me, it sounds like you think equity placings are ALWAYS an evil. I would strongly disagree with this 3/5
Finally: personally, I think commentators online should present their own thoughts as opinion - not as a command or fact, as you have done in your final sentence. I believe that many investors will feel that you are trying to state that your own investing philosophy is the... 4/5
..ONLY philosophy that one should have. On the contrary, I believe that many investors - particularly those in the FinTwit community - feel that the investment philosophy you have implied with your "keep away unless you enjoy pouring money away" statement is, in fact, archaic 5/5
• • •
Missing some Tweet in this thread? You can try to
force a refresh
There are many stale holders who have been underwater for 18+ months, who will be happy to take some cash out now, in this ongoing cost of living crisis. That is understandable.
There will also be traders exiting, having positioned for this update.
Furthermore, the...
2/20
...wider investment community has not yet heard of, and even more so not appreciated the significance of, today's news at #AVCT.
Finally, I will state with a high degree of confidence that today's RNS opens the floodgates for numerous more updates in the near future.
Volume returning really nicely to the small cap space, which is creating excellent trading conditions.
My average holding period in the Short-term Trading Portfolio is still around 16 sessions / 3 weeks.
Seemingly contrary to many, I consider trade entries based both on..
2/18
...fundamentals (see two recent successful trades in MMAG and SPEC, with rationales for trades founded on earnings metrics), and on stories and associated sentiment (BSFA being most recent example).
I don't subscribe to only utilizing one or the other; the same way as I...
@AnEarlofWisdom Hi Earl, I can't see any of the posts, as I'm blocked by those accounts (or I've blocked!), but I've been told there's a lot of scaremongering about various things:
1) Delay in trial; 2) Dox not activating much in TME; 3) Low cash balance, and thus possible placing coming.
1/8
@AnEarlofWisdom On the contrary, except for Cohorts 1 and 2 taking longer than expected (due to patient withdrawals - nothing whatsoever to do with #AVA6000 itself), #AVCT's progress in 2022 could not be stronger.
The DE to 200mg/m2 was the ultimate target, so that nullifies point 2) ⬆️.
2/8
@AnEarlofWisdom Licensing deals for targeted oncology drugs - even those at pre-clinical stage, like 3996 - have been monstrous in recent times (e.g. $100m cash upfront for an antibody-drug conjugate, just last month ⬇️).
...substrate to FAP is so high that the concentration ratio of active doxorubicin in the tumour : healthy tissue, will negate the requirement for increase in dose size. [My view!]
Enough dox is already becoming active in the tumour micro-environment, at the current...
3/8
$SGEN specializes in antibody-drug conjugates ('ADC') - a relatively novel form of targeted cancer treatment.
@avacta's targeted cancer treatment platform, preCISION, has the real potential of generating pro-chemotherapies that are MORE targeted than ADCs, and thus...
2/6
...also potentially capable of delivering a more potent drug payload.
#AVCT will be announcing the results of the first preCISION prodrug P1 trial (AVA6000) in the next few months.
Success will mean the platform could be used to modify many other existing chemotherapies.
3/6